Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients. Stay ahead of policy, cost, and ...

—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...

Please provide your email address to receive an email when new articles are posted on . Most patients with nonsquamous NSCLC treated at academically-affiliated community clinics received ...

FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, ...

Exploring barriers to completing referral appointments for cancer genetic services in a rural state. Is federal housing assistance associated with earlier-stage cancer diagnosis? Evidence from the new ...

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets. Multivariate analysis for patients undergoing molecular testing.

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous non–small cell lung cancer.